CVR number 32324304
Industry 46.4610 Wholesale of pharmaceutical goods

MOMEDICO ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  2.1% 2.2% 1.8% 1.6% 2.6%  
Credit score (0-100)  67 65 70 73 62  
Credit rating  A BBB A A BBB  
Credit limit (kDKK)  0.1 0.0 0.7 6.4 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Net sales  0 0 0 0 0  
Gross profit  1,209 1,674 1,742 2,454 4,215  
EBITDA  234 387 947 945 1,844  
EBIT  142 259 947 945 1,844  
Pre-tax profit (PTP)  133.6 248.0 943.4 942.4 1,824.9  
Net earnings  102.6 186.7 725.5 725.6 1,400.7  
Pre-tax profit without non-rec. items  134 248 943 942 1,825  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Tangible assets total  458 330 0.0 0.0 0.0  
Shareholders equity total  410 484 806 1,031 1,932  
Interest-bearing liabilities  336 1.1 10.1 186 192  
Balance sheet total (assets)  1,311 1,438 2,482 4,094 5,192  
Net Debt  -97.6 -404 -708 -2,240 -2,022  
 
See the entire balance sheet

Volume 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,209 1,674 1,742 2,454 4,215  
Gross profit growth  -4.1% 38.4% 4.1% 40.9% 71.7%  
Employees  0 0 0 0 5  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,311 1,438 2,482 4,094 5,192  
Balance sheet change%  32.1% 9.7% 72.6% 64.9% 26.8%  
Added value  233.6 387.3 946.9 944.6 1,844.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -168 -256 -330 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  11.8% 15.5% 54.4% 38.5% 43.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  12.4% 18.9% 48.3% 28.8% 39.9%  
ROI %  17.5% 39.8% 142.4% 93.1% 110.8%  
ROE %  24.8% 41.8% 112.5% 79.0% 94.5%  

Solidity 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Equity ratio %  31.3% 33.7% 32.4% 35.1% 37.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -41.8% -104.4% -74.8% -237.2% -109.6%  
Gearing %  81.8% 0.2% 1.3% 18.0% 10.0%  
Net interest  0 0 0 0 0  
Financing costs %  2.5% 6.7% 62.4% 3.5% 13.9%  

Liquidity 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Quick Ratio  1.0 1.0 1.3 1.9 1.5  
Current Ratio  1.0 1.3 1.7 1.4 1.6  
Cash and cash equivalent  433.3 405.4 718.3 2,425.9 2,214.1  

Capital use efficiency 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  20.5 250.8 1,019.3 1,202.1 1,931.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 369  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 369  
EBIT / employee  0 0 0 0 369  
Net earnings / employee  0 0 0 0 280